Abstract
Introduction
Previous studies have demonstrated a slowed dynamic increase in pulmonary oxygen uptake ( O2P) in patients with chronic obstructive pulmonary disease (COPD) (Nery et al. 1982; Palange et al. 1995; Chiappa et al. 2008) . Patients with COPD typically experience locomotor muscle fatigue as a result of pulmonary system limitations (Amann et al. 2010) ; systemic and peripheral O2 delivery may be reduced, leading to slowed O2 kinetics, which become limited by the availability of O2 (Chiappa et al. 2008 ) . Moreover, lung hyperinflation secondary to underlying lung disease can overload the respiratory muscles, leading to reduced muscle blood flow. This, in turn, results in muscular weakness and fatigue, and increases the recruitment of accessory inspiration muscles, contributing to exercise intolerance (Polkey et al. 1996; Amann et al. 2010; ; Chiappa et al. 2014; Vieira et al. 2014) .
Recent studies have shown that inspiratory muscle changes affect peripheral skeletal muscles (Gosselink et al. 1996; Borghi-Silva et al. 2008; Gosselink et al. 2011; Chiappa et al. 2014) . For example, a previous study in healthy individuals demonstrated an inverse correlation between changes in respiratory work and blood flow to locomotor muscles, at maximal aerobic capacity (Harms et al. 1997) , which may lead to exacerbation of dyspnea and contribute to exercise intolerance. However, impaired respiratory muscle dysfunction may also be implicated in impaired exercise performance, commonly observed in patients with COPD (Singer et al. 2011) . There is currently a lack of information on the association between inspiratory muscle strength and slowed O2 kinetics observed in patients with moderate to severe COPD. Thus, we tested the hypothesis that slowed O2 kinetics, commonly observed in COPD patients (Chiappa et D r a f t al. 2008) , are associated with inspiratory muscle weakness and reduced minute ventilation (Poole and Jones 2012) .
Materials and Methods

Patients and Study Design
A cross-sectional study was conducted including patients with a previous diagnosis of COPD based on the criteria of the Global Initiative Rating for Chronic Obstructive Lung Disease -GOLD (Vestbo et al. 2013) . Patients were included in the study if they 1) were diagnosed with COPD (GOLD) with FEV1 < 40% of predicted (Vestbo et al. 2013) ; 2) had self-reported dyspnea and/or fatigue during at least one activity of daily living (based on the 6-20 Borg Category-Ratio Scale (CRS) (Wilson and Jones 1989); and 3) were able to adequately perform the PImax and PEmax tests. Patients were excluded from the study if they 1) were engaged in any pulmonary rehabilitation program; 2) had a cough or any sputum production, for at least three consecutive months in the previous two years, consistent with a diagnosis of chronic bronchitis (Menezes et al. 1994) ; 3) had a severe or very severe air flow limitation (FEV1 < 30% of predicted); 4) had a history of intolerance to exercise (distance traveled on the Six-Minute Walk Test [6MWT] < 350 m; (Guyatt et al. 1985) ; 5) had a musculoskeletal or neurological condition, that might affect their exercise performance, symptomatic heart disease, or had received previous pulmonary surgery, 6) had experienced acute exacerbation of their COPD requiring a change; in pharmacological management within the previous two months; 7) were taking oral corticosteroids; 8) had changed their medication D r a f t 5 dosage within the previous 12 weeks in the absence of acute exacerbation; or 9) had experienced heart failure.
Before enrollment into the study, patients' lung function was optimized using longacting bronchodilators and corticosteroids and, if needed, patients could use shortacting bronchodilators to optimize their performance or as a rescue therapy (120 µg of salbutamol/20 µg of ipratropium, Combivent Boehringer Ingelheim GmbH, Ingelheim, Germany). The procedures and potential risks were explained to patients in detail. This study was conducted in compliance with the Declaration of Helsinki and received approval from the Human Research Ethics Committee, University Center of Serra Gaúcha, Caxias do Sul, Brazil. Written informed consent was provided by each participant.
Procedures
After screening, participants were allocated into one of two groups according to either the presence or absence of inspiratory muscle weakness (IMW+ or IMW-, respectively; Figure 1 ). At their first visit, participants performed skeletal respiratory muscle strength tests, lung function tests and the six-minute walk test (6-MWT). At their second visit, incremental cardiopulmonary exercise testing was performed along with tests of handgrip strength and endurance. At their third visit, the constant work rate exercise test was performed to measure O2 kinetics. During all phases of the study, Peripheral oxygen saturation (SpO2) was measured continuously in all patients.
Skeletal Muscle Function
First, handgrip strength was evaluated by measuring the maximum voluntary contraction (MVC). Second, static handgrip endurance was evaluated, in the dominant arm, by performing an exercise at an intensity of 30% MVC for 3 min.
Respiratory Muscle Function
Inspiratory and expiratory muscle function testing was performed using a pressure transducer (MVD-500 V.1.1 Microhard System, Globalmed, Porto Alegre, Brazil) connected to a system with two unidirectional valves (DHD Inspiratory Muscle Trainer, Chicago, Illinois, USA; (Dall'Ago et al. 2006) . A hole, measuring 2 mm in diameter, was used to keep the glottis open and avoid an increase in pressure due to contraction of the facial muscles (Black and Hyatt 1969; ; Tzelepis et al. 1994a; Tzelepis et al. 1994b; Dall'Ago et al. 2006) . After two normal tidal breaths, the participant slowly exhaled to a lung volume close to the residual volume, and then performed maximum inspiration against the occluded circuit. PEmax were performed after deep inspiration and Total Lung Capacity (TLC) was reached. To measure PImax and PEmax, the patients were instructed to sit and use a nose clip (Black and Hyatt 1969; Leech et al. 1983 ). The test was repeated six times to mitigate the learning effect, with a one-minute interval between each attempt. The greatest single value of PImax and PEmax were recorded, where the difference between the two best efforts was no greater than 10% (Nava et al. 1993 ). PImax and PEmax were verified via direct visualization. Predicted values were corrected for age, sex, and weight (Neder et al. 1999) . Inspiratory muscle weakness was defined as a PImax value below 60 cm H2O (Lotters et al. 2002) .
Inspiratory Muscle Incremental and Endurance Test
D r a f t
An inspiratory muscle incremental endurance test was performed, in which the patients breathed continuously through a mouthpiece connected to a threshold inspiratory muscle trainer. First, a resistance generating device (K5 POWER breathe, United Kingdom) was used with an initial load of 50% PImax, and loads of 10% PImax were added incrementally every 3 minutes until the patient was unable to continue breathing (Dall'Ago et al. 2006) . The maximum inspiratory pressure that the subject could sustain for at least 1 minute (Pthmax) was recorded and the Pthmax/PImax ratio was calculated, and used as an indicator of inspiratory muscle performance.
Second, the patient breathed against a constant inspiratory sub-maximum load, equivalent to 80% Pthmax, and the time-to-task-failure was recorded, and used as an indicator of inspiratory muscle endurance time ( (Ribeiro et al. 2006 ).
Six-Minute Walk Test
The maximum distance covered during the 6-MWT was used as an indicator of submaximal functional capacity (Guyatt et al. 1985; ATS Committee 2002; Hernandes et al. 2011 ). The test was performed on a 25-m course without supplemental additional oxygen but with verbal encouragement, in accordance with the American Thoracic Society Guidelines ATS 2002; (ATS Commitee 2002). Respiratory rate, heart rate, pulse oximetry, and blood pressure were monitored during and after the test. Dyspnea was determined using the 6-20 Borg category-ratio scale (Wilson and Jones 1989) . The distance walked was measured and expressed as a percentage of the predicted value (Enright and Sherrill 1998; Enright et al. 1998) .
Lung Function Test
D r a f t
Spirometry was performed at rest and after inhalation of salbutamol (400 g).
Participants performed at least three acceptable expiratory maneuvers. As recommended by the American Thoracic Society (Miller et al. 2005) , forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1/FVC were measured (Koko PFT, Nspire Health, USA). Benchmarks, approved by the European Respiratory Society, were used for the analysis of FVC, FEV1, and inspiratory capacity (IC; (Wanger et al. 2005) .
Cardiopulmonary Exercise Testing
All participants performed a symptom-limited cardiopulmonary exercise test on an exercise bike (IMBRAMED 10200, Porto Alegre, Brazil). Participants began by resting on the ergometer for 5 to 10 minutes to allow gas exchange measurements to stabilize.
Participants then began unloaded cycling for two minutes, after which the work rate was increased by 5 or 10 W every two minutes until their limit of tolerance was reached.
Selection of incremental level was achieved according to patient's level of tolerance, with lower levels for patients with more impaired lung function, and higher levels for patients with less impaired lung function. In this way, we guaranteed a minimum exercise time of between 8 to 12 minutes.
Twelve-lead electrocardiographic tracings were obtained every minute (Nihon Khoden Corp., Tokyo, Japan). Blood pressure was measured every two minutes with a standard cuff sphygmomanometer. Expired gases were quantified with aliquots 10 s average using a computerized gas analyzer (Cortex Metalyzer, 2B system, Leipzig, Germany).
Although our system was breath-by-breath, the calculation of O2 average every 10 s enabled analysis and graph construction of O2 kinetics. Peak oxygen uptake ( D r a f t O2peak) was expressed as a percentage, predicted according to age, sex, and weight, as per Hansen et al (Hansen et al. 1984 ). The gas exchange threshold (GET) is defined as the breakpoint in the breath-by-breath values of carbon dioxide output ( CO2) plotted against oxygen uptake ( O2), caused by an increase in CO2 from bicarbonate buffering of lactic acid (Beaver et al. 1986a) . The O2 at the GET was estimated by the gas exchange method, by visually inspecting the inflection point of CO2 with respect to O2 (modified V-slope; (Beaver et al. 1986b) , and ventilatory method, when E/ O2 and expired oxygen pressure (PETO2) increases while E/ CO2 and expired carbon dioxide pressure (PETCO2) remain stable. For accurate identification of the GET, two regions were discarded from the analysis: 1) the initial 2 min-during which Respiratory Quotient (R) decreases-to account for the effects of transient CO2 storage, and 2) the points beyond the respiratory compensation point. The reading was performed independently by two experienced observers, without knowledge of the other results or subject identities. The alveolar ventilation (AV) was calculated by the following formula:
Eq. (1)
Were VD / VT is the dead space to tidal volume ratio.
The VD / VT measurement was calculated from the PaCO2 values, obtained from the following equation:
where m and c are the slope and E-intercept of the E -CO2 relationship, respectively. The PaCO2 value was obtained through an arterial blood gas analysis, with arterial blood obtained via a single radial artery puncture, at three different times of test in rest, middle and end (ATS and ACCP 2003; Ward 2007) . Oxygen pulse at peak D r a f t exercise was calculated from the ratio of VO2 and Heart Rate (HR) at peak and used as an index of stroke volume (Montes de Oca et al. 1996; Benditt et al. 1997; Cordova et al. 1997; Stammberger et al. 1998; Laukkanen et al. 2006; Travers et al. 2007; Vassaux et al. 2008; Come et al. 2012) .
Constant Work Rate Test. The difference between O2p at the GET ( O2p GET) and
O2p at peak exercise ( O2p peak; ∆ O2p peak-GET) were determined from the ramp test, performed on an electromagnetically-braked cycle ergometer (Metalyzer 3B, CPX System, Cortex, Leipzig, Germany). Subjects performed constant work rate exercise at 80% ∆ O2p peak-GET (~80% peak incremental work rate) initiated from a baseline of unloaded pedaling, as described elsewhere (Chiappa et al. 2008) . Subjects were instructed to maintain a constant pedaling cadence until a tolerable duration was reached (Tlim, min). Oxygen uptake ( O2, mL/min), carbon dioxide output ( CO2, mL/min), and minute ventilation ( E, L/min) were measured breath-by-breath using a computer-based system. Gas exchange, ventilatory and cardiovascular variables were averaged every 5 s. O2peak was defined as the greatest value achieved during the test.
Heart rate (HR, bpm) was determined using the R-R interval from a 3-lead electrocardiogram. Subjects were asked to rate their 'shortness of breath' at exercise cessation using the 6-20 Borg's CRS.
Kinetics Analysis. The breath-by-breath O2 data was interpolated second-by-second, prior to kinetic analysis (SigmaPlot 11.0, Systat Software, San Jose, CA). The O2 responses to exercise intensity were characterized by the presence of a slow component (Poole et al. 1988; Gaesser and Poole 1996; Chiappa et al. 2008; Jones et al. 2011 ). 
Data analysis
The data are expressed as means ± standard deviations (SD), and all analyses were performed using the SigmaPlot software program (SigmaPlot 11.0, Richmond, USA).
One-way analysis of variance (ANOVA) was used to compare the baseline differences between groups. 
Results
Between August and December 2014, 50 patients with COPD were screened for inclusion in the study. Five patients did not meet the eligibility criteria (4 did not complete study, and 1 had arrhythmia). Thus, 45 patients were allocated to the two groups; 22 patients were allocated to the IMW+ group and 23 patients were allocated to the IMW-group (Figure 1 ).
The demographic and spirometric characteristics of the two groups were similar ( Table   1 ), except that IMW+ patients had lower respiratory muscle and handgrip strength, and lower respiratory muscle endurance. Table 2 shows the outcomes of the 6-MWT, incremental exercise test, and constant work rate exercise test. The IMW+ patients had lower 6-MWT and 6-MWT/Borg CRS values than the IMW-patients (p < 0.05). O2 peak was significantly lower in the IMW+ patients compared to the IMW-patients (1170 ± 210 vs. 1823 ± 360 mL/min, p < 0.05).
O2/HR was significantly lower in the IMW+ patients compared to the IMW-patients (p < 0.05). During the constant work test, the IMW-patients attained a lower time constant (τ) and MRT compared to the IMW+ patients (p < 0.05; Figure 2 ). No significant between-group differences were found with respect to baseline O2, primary O2
amplitude, or primary time delay. Minute ventilation, alveolar ventilation, and SpO2
were assessed at isotime during the constant work rate exercise test. The IMW+ patients D r a f t 13 had greater minute ventilations throughout ( Figure 3 ) and greater alveolar ventilations at peak exercise. The IMW+ patients had greater exercise induced arterial desaturations at peak exercise compared to the IMW-patients (89.7 ± 3.2 vs 94.6 ± 2.7 %, p = 0.02; Figure 3 ).
We used multiple regression analyses to explore the associations between 6-MWT distance, VO2 kinetics, VO2peak and PImax. Regression analyses revealed significant correlations between the 6-MWT and PImax (r 2 = 0.69; p < 0.001), the 6-MWT and tau O2 (r 2 = 0.37; p < 0.01), and O2 peak with PImax (r 2 = 0.59; p < 0.01; Figure 4 ).
Discussion
Our data indicates that inspiratory muscle weakness in COPD is associated with low 6-MWT distances and slowed VO2 kinetics.
According to previous studies (Rochester and Braun 1985; Begin and Grassino 1991; Saey et al. 2014) , respiratory muscle strength is affected in patients with COPD (Gosselink et al. 1996) . In the present investigation, a 48% prevalence rate of PImax < 60 cmH2O was found among patients with severe or very severe COPD, which is compatible with inspiratory muscle weakness (Ottenheijm et al. 2007; Gosselink et al. 2011 ). Moreover, the average absolute value of PImax found was in according to a previous meta-analysis (Lotters et al. 2002) . Interestingly, the presence of inspiratory muscle weakness may be associated with impaired pulmonary function in COPD patients. However, this does not adequately reflect systemic manifestations that contribute to reduced exercise performance (Celli et al. 2004) . We have shown that slower oxygen uptake kinetics are closely associated with hyperinflation of the lung(s) in COPD patients (Chiappa et al. 2008; Chiappa et al. 2009 ). Interestingly, strategies that D r a f t reduce lung hyperinflation may accelerate oxygen uptake kinetics, and improve exercise performance (Chiappa et al. 2009 ).
In the present study, we found a significant correlation between the 6-MWT and PImax, suggesting that inspiratory muscle weakness is associated with decreased functional capacity. Recently, Singer et al found a modest, but statistically significant, association between the distance walked in the 6-MWT and respiratory muscle weakness, in patients with COPD (Singer et al. 2011 ). However, this study included all GOLD severity levels, which may have affected the results. In our study, we only included severe to very severe COPD, which may have resulted in stronger correlations because of the avoidance of a ceiling effect in the association between PImax and the 6-MWT, observed in patients with mild to moderate COPD (Singer et al. 2011) . Studies have demonstrated a strong correlation between FEV1 and the 6-MWT, which is a predictor of exercise capacity (Ijiri et al. 2014) , suggesting that patients with peripheral and respiratory muscle weakness have reduced exercise capacity (Singer et al. 2011 ). In the present study, this response was dependent upon inspiratory muscle strength (r = 0.83; p < 0.05). Reduced muscle strength can result in diaphragm fatigue in patients with COPD, leading to the increased recruitment of accessory muscles and reducing ventilatory efficiency, as well as increasing the blood flow requirement to respiratory muscles during exercise. and, potentially, O2 delivery (Pessoa et al. 2013 ).
In patients with COPD, there is an exacerbation of respiratory sensitivity, affecting both the central and peripheral stimulation of chemoreceptors (Chiappa et al 2014) . This is due to an overload of inspiratory muscles, typical of patients with COPD that have greater elastic and resistive breathing work (Gosker et al. 2003) . These modifications can reflexively induce sympathetic vasoconstriction, and reduce blood flow to skeletal muscles during exercise (Harms et al. 1998; St Croix et al. 2000) , affecting O2 kinetics.
We have shown that patients with COPD have slower O2 kinetics (Chiappa et al.
2008), which may be due to limitations in the convective and/or diffusive transport of O2 to skeletal muscle mitochondria and intramyocyte metabolic machinery.
Interestingly, changes associated with IMW can, therefore, result in reduced blood flow and/or O2 delivery to the locomotor muscles, which could limit O2 kinetics during constant work rate exercise. Diaphragm fatigue in COPD is known to contribute to sympathetic vasoconstriction of the vessels supplying the legs and may potentially limit O2 kinetics (Nery et al. 1982; Palange et al. 1995; Somfay et al. 2002; Richardson et al. 2004; Borghi-Silva et al. 2008; Chiappa et al. 2008; Neder 2008) . Alternatively, COPD patients with IMW had the greatest functional impairments, and therefore, were likely to have the greatest peripheral deconditioning . As intramuscular mitochondrial expression is the primary determinant of O2 kinetics in muscle cells (Poole and Jones 2012; Wust et al. 2013) , it is also possible that deconditioning of both the respiratory and locomotor muscles underlies the association between PImax and O2 kinetics.
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An important limitation to this study was our use of a single transition to determine O2 kinetics, which may limit the resolution of small differences in kinetic response, especially O2. However, the differences between the IMW+ and IMW-patients were large enough to be detected statistically, as suggested by the study of Puente-Maestu et al (Puente-Maestu et al. 2001) . Additionally, we used a constant pedaling cadence to determine Tlim at an intensity of 80%∆ O2 peak-GET, which elicits a O2 slow component and rapid intolerance, and thus O2 kinetics at this intensity may differ from O2 kinetics below GET. However, we have successfully used this methodology in a previous study (Chiappa et al. 2008 ).
Our findings indicate that inspiratory muscle weakness is associated with slow O2 kinetics and exercise intolerance in patients with COPD. It is currently unclear whether enhancing respiratory muscle strength, for example through inspiratory muscle training (Charususin et al. 2013) , would help reverse slowed O2 kinetics in patients with reduced respiratory muscle strength. Nevertheless, inspiratory muscle training in COPD may result in significant increases in aerobic capacity and exercise tolerance, as well as reduced dyspnea and increased quality of life (Kern and Kaushal 2014) .
Conclusion
This study demonstrated that inspiratory muscle weakness in COPD patients is associated with low functional capacity (low 6MWT) and slowed O2 kinetics. Charususin, N., Gosselink, R., Decramer, M., McConnell, A., Saey, D., Maltais, F., et al. 2013 . 
Conflicts of interest
